News

Decreasing RBC transfusions saves center $1 million


 

Photo by Elise Amendola

Blood for transfusion

Researchers have reported that interventions designed to decrease the need for red blood cell (RBC) transfusions proved effective when implemented at an academic medical center, and they resulted in an annual cost savings of more than $1 million.

The interventions included educational tools, a “best practice advisory,” and changes to the computerized provider order entry system.

They enabled the medical center to reduce multi-unit transfusions by 67.1% and transfusions for patients with hemoglobin (Hb) values of at least 7 g/dL by 47.4%.

Ian Jenkins, MD, of University of California San Diego (UCSD) Health, and his colleagues reported these results in The Joint Commission Journal on Quality and Patient Safety.

This work began with a multidisciplinary team at UCSD Health reviewing the transfusion literature on clinical trials, meta-analyses, guidelines, and improvement efforts.

The team used the information gleaned from this review and implemented the following interventions in an attempt to reduce unnecessary RBC transfusions:

  • Educational tools (handouts, a video, PowerPoint presentations, etc)
  • Enhancements to the health system’s computerized provider order entry system (eg, changing default RBC dose from 2 units to 1 unit)
  • A “best practice advisory” intended to reduce unnecessary blood product use and costs by using real-time clinical decision support, a process for providing information at the point of care to help inform decisions about a patient’s care.

To assess the impact of their interventions, the researchers evaluated data on most non-infant, inpatient RBC transfusions given at UCSD Health between January 1, 2014, and September 30, 2016.

They excluded units given to patients with gastrointestinal bleeding and units given within 12 hours of a surgical procedure. The team said they excluded these transfusions because of the higher probability of unstable blood volume or special circumstances that might justify off-protocol transfusion.

The researchers then calculated the rate of inpatient RBC units transfused per 1000 patient-days (without exclusions), the percentage of inpatient RBC units transfused for patients with Hb ≥ 7 g/dL, and the percentage of multi-unit RBC transfusions, divided into 3 periods:

  • Pre-intervention or baseline (January 1, 2014–September 30, 2014)
  • During the intervention (October 1, 2014–April 30, 2015)
  • Post-intervention (May 1, 2015–September 30, 2016).

There were 36,386 RBC units administered during the study period, which was 464,424 patient days.

Multi-unit transfusions decreased from 59.9% at baseline to 41.7% during the intervention period and 19.7% during the post-intervention period (P<0.0001).

Transfusions in patients with Hb values ≥ 7 g/dL decreased from 72.3% at baseline to 57.8% during the intervention period and 38.0% during the post-intervention period (P<0.0001).

The total RBC transfusion rate (units per 1000 patient-days) decreased from 89.8 at baseline to 78.1 during the intervention period and 72.7 during the post-intervention period (P<0.0001).

The estimated savings, based on a cost of $250 per RBC unit, was about $1,050,750 per year.

Recommended Reading

England, Scotland to shorten deferral for high-risk blood donors
MDedge Hematology and Oncology
Study supports wider use of dried blood samples
MDedge Hematology and Oncology
Assay available to screen donated blood for Zika
MDedge Hematology and Oncology
Device reduces blood draw contamination
MDedge Hematology and Oncology
Hemoglobin nanoparticles could serve as blood substitute
MDedge Hematology and Oncology
FDA clears test for individual WBD platelet units
MDedge Hematology and Oncology
FDA authorizes use of first fully automated Zika IgM test
MDedge Hematology and Oncology
EC publishes guides on patient blood management
MDedge Hematology and Oncology
Studies support Zika screening in entire US blood supply
MDedge Hematology and Oncology
Donor screening assays more sensitive than diagnostic assays for Zika
MDedge Hematology and Oncology